Intrinsic value of Alnylam Pharmaceuticals - ALNY

Previous Close

$122.88

  Intrinsic Value

$2.29

stock screener

  Rating & Target

str. sell

-98%

Previous close

$122.88

 
Intrinsic value

$2.29

 
Up/down potential

-98%

 
Rating

str. sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of ALNY stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

Please visit our new site that uses elements of artificial intelligence for stock valuation: artificial intelligence value of Alnylam Pharmaceuticals (ALNY) stock.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  14.63
  21.40
  19.76
  18.28
  16.96
  15.76
  14.68
  13.72
  12.84
  12.06
  11.35
  10.72
  10.15
  9.63
  9.17
  8.75
  8.38
  8.04
  7.74
  7.46
  7.22
  6.99
  6.79
  6.62
  6.45
  6.31
  6.18
  6.06
  5.95
  5.86
  5.77
Revenue, $m
  47
  57
  68
  81
  95
  109
  125
  143
  161
  180
  201
  222
  245
  269
  293
  319
  346
  373
  402
  432
  464
  496
  530
  565
  601
  639
  679
  720
  763
  807
  854
Variable operating expenses, $m
 
  469
  561
  664
  776
  899
  1,031
  1,172
  1,323
  1,482
  1,650
  1,827
  2,013
  2,207
  2,409
  2,620
  2,839
  3,067
  3,305
  3,551
  3,807
  4,074
  4,351
  4,638
  4,938
  5,249
  5,573
  5,911
  6,263
  6,630
  7,013
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  472
  469
  561
  664
  776
  899
  1,031
  1,172
  1,323
  1,482
  1,650
  1,827
  2,013
  2,207
  2,409
  2,620
  2,839
  3,067
  3,305
  3,551
  3,807
  4,074
  4,351
  4,638
  4,938
  5,249
  5,573
  5,911
  6,263
  6,630
  7,013
Operating income, $m
  -425
  -412
  -493
  -583
  -682
  -789
  -905
  -1,029
  -1,162
  -1,302
  -1,449
  -1,605
  -1,768
  -1,938
  -2,116
  -2,301
  -2,493
  -2,694
  -2,902
  -3,119
  -3,344
  -3,578
  -3,821
  -4,074
  -4,336
  -4,610
  -4,895
  -5,191
  -5,500
  -5,823
  -6,159
EBITDA, $m
  -410
  -394
  -472
  -558
  -653
  -756
  -867
  -986
  -1,113
  -1,247
  -1,388
  -1,537
  -1,693
  -1,856
  -2,026
  -2,204
  -2,388
  -2,580
  -2,780
  -2,987
  -3,203
  -3,427
  -3,660
  -3,902
  -4,154
  -4,416
  -4,688
  -4,972
  -5,269
  -5,577
  -5,899
Interest expense (income), $m
  1
  5
  8
  11
  14
  17
  21
  25
  30
  34
  39
  44
  50
  56
  62
  68
  75
  81
  88
  96
  103
  111
  120
  128
  137
  147
  156
  166
  177
  188
  199
Earnings before tax, $m
  -410
  -417
  -501
  -594
  -696
  -807
  -926
  -1,055
  -1,191
  -1,336
  -1,489
  -1,649
  -1,818
  -1,994
  -2,177
  -2,369
  -2,568
  -2,775
  -2,991
  -3,215
  -3,447
  -3,689
  -3,941
  -4,202
  -4,474
  -4,757
  -5,051
  -5,358
  -5,677
  -6,010
  -6,358
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -410
  -417
  -501
  -594
  -696
  -807
  -926
  -1,055
  -1,191
  -1,336
  -1,489
  -1,649
  -1,818
  -1,994
  -2,177
  -2,369
  -2,568
  -2,775
  -2,991
  -3,215
  -3,447
  -3,689
  -3,941
  -4,202
  -4,474
  -4,757
  -5,051
  -5,358
  -5,677
  -6,010
  -6,358

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  627
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,263
  771
  923
  1,092
  1,277
  1,479
  1,696
  1,929
  2,176
  2,439
  2,716
  3,007
  3,312
  3,631
  3,964
  4,310
  4,671
  5,047
  5,437
  5,843
  6,265
  6,703
  7,158
  7,632
  8,124
  8,637
  9,170
  9,726
  10,305
  10,909
  11,539
Adjusted assets (=assets-cash), $m
  636
  771
  923
  1,092
  1,277
  1,479
  1,696
  1,929
  2,176
  2,439
  2,716
  3,007
  3,312
  3,631
  3,964
  4,310
  4,671
  5,047
  5,437
  5,843
  6,265
  6,703
  7,158
  7,632
  8,124
  8,637
  9,170
  9,726
  10,305
  10,909
  11,539
Revenue / Adjusted assets
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
  0.074
Average production assets, $m
  72
  87
  104
  123
  144
  166
  191
  217
  245
  274
  306
  338
  373
  409
  446
  485
  526
  568
  612
  658
  705
  754
  806
  859
  914
  972
  1,032
  1,095
  1,160
  1,228
  1,299
Working capital, $m
  540
  -106
  -126
  -150
  -175
  -203
  -232
  -264
  -298
  -334
  -372
  -412
  -454
  -497
  -543
  -590
  -640
  -691
  -745
  -800
  -858
  -918
  -981
  -1,045
  -1,113
  -1,183
  -1,256
  -1,332
  -1,412
  -1,494
  -1,580
Total debt, $m
  150
  223
  305
  396
  496
  604
  721
  846
  980
  1,121
  1,271
  1,428
  1,592
  1,764
  1,943
  2,130
  2,325
  2,527
  2,738
  2,956
  3,184
  3,420
  3,665
  3,921
  4,186
  4,462
  4,750
  5,049
  5,361
  5,687
  6,026
Total liabilities, $m
  343
  416
  498
  589
  689
  797
  914
  1,039
  1,173
  1,314
  1,464
  1,621
  1,785
  1,957
  2,136
  2,323
  2,518
  2,720
  2,931
  3,149
  3,377
  3,613
  3,858
  4,114
  4,379
  4,655
  4,943
  5,242
  5,554
  5,880
  6,219
Total equity, $m
  920
  355
  426
  504
  589
  682
  782
  889
  1,003
  1,124
  1,252
  1,386
  1,527
  1,674
  1,827
  1,987
  2,154
  2,327
  2,507
  2,694
  2,888
  3,090
  3,300
  3,518
  3,745
  3,982
  4,228
  4,484
  4,751
  5,029
  5,319
Total liabilities and equity, $m
  1,263
  771
  924
  1,093
  1,278
  1,479
  1,696
  1,928
  2,176
  2,438
  2,716
  3,007
  3,312
  3,631
  3,963
  4,310
  4,672
  5,047
  5,438
  5,843
  6,265
  6,703
  7,158
  7,632
  8,124
  8,637
  9,171
  9,726
  10,305
  10,909
  11,538
Debt-to-equity ratio
  0.163
  0.630
  0.720
  0.790
  0.840
  0.890
  0.920
  0.950
  0.980
  1.000
  1.020
  1.030
  1.040
  1.050
  1.060
  1.070
  1.080
  1.090
  1.090
  1.100
  1.100
  1.110
  1.110
  1.110
  1.120
  1.120
  1.120
  1.130
  1.130
  1.130
  1.130
Adjusted equity ratio
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -410
  -417
  -501
  -594
  -696
  -807
  -926
  -1,055
  -1,191
  -1,336
  -1,489
  -1,649
  -1,818
  -1,994
  -2,177
  -2,369
  -2,568
  -2,775
  -2,991
  -3,215
  -3,447
  -3,689
  -3,941
  -4,202
  -4,474
  -4,757
  -5,051
  -5,358
  -5,677
  -6,010
  -6,358
Depreciation, amort., depletion, $m
  15
  17
  21
  25
  29
  33
  38
  43
  49
  55
  61
  68
  75
  82
  89
  97
  105
  114
  122
  132
  141
  151
  161
  172
  183
  194
  206
  219
  232
  246
  260
Funds from operations, $m
  -291
  -399
  -480
  -569
  -667
  -773
  -888
  -1,011
  -1,142
  -1,281
  -1,428
  -1,582
  -1,743
  -1,912
  -2,088
  -2,272
  -2,463
  -2,662
  -2,868
  -3,083
  -3,306
  -3,538
  -3,779
  -4,030
  -4,291
  -4,562
  -4,845
  -5,139
  -5,445
  -5,765
  -6,098
Change in working capital, $m
  17
  -19
  -21
  -23
  -25
  -28
  -30
  -32
  -34
  -36
  -38
  -40
  -42
  -44
  -46
  -48
  -49
  -51
  -53
  -56
  -58
  -60
  -62
  -65
  -67
  -70
  -73
  -76
  -79
  -83
  -86
Cash from operations, $m
  -308
  -381
  -459
  -546
  -642
  -746
  -858
  -979
  -1,108
  -1,245
  -1,390
  -1,542
  -1,701
  -1,868
  -2,043
  -2,224
  -2,413
  -2,610
  -2,815
  -3,028
  -3,249
  -3,478
  -3,717
  -3,965
  -4,223
  -4,492
  -4,771
  -5,063
  -5,366
  -5,682
  -6,012
Maintenance CAPEX, $m
  0
  -14
  -17
  -21
  -25
  -29
  -33
  -38
  -43
  -49
  -55
  -61
  -68
  -75
  -82
  -89
  -97
  -105
  -114
  -122
  -132
  -141
  -151
  -161
  -172
  -183
  -194
  -206
  -219
  -232
  -246
New CAPEX, $m
  -65
  -15
  -17
  -19
  -21
  -23
  -24
  -26
  -28
  -30
  -31
  -33
  -34
  -36
  -37
  -39
  -41
  -42
  -44
  -46
  -47
  -49
  -51
  -53
  -55
  -58
  -60
  -63
  -65
  -68
  -71
Cash from investing activities, $m
  143
  -29
  -34
  -40
  -46
  -52
  -57
  -64
  -71
  -79
  -86
  -94
  -102
  -111
  -119
  -128
  -138
  -147
  -158
  -168
  -179
  -190
  -202
  -214
  -227
  -241
  -254
  -269
  -284
  -300
  -317
Free cash flow, $m
  -165
  -410
  -494
  -586
  -687
  -797
  -916
  -1,044
  -1,180
  -1,324
  -1,476
  -1,636
  -1,803
  -1,979
  -2,162
  -2,352
  -2,551
  -2,758
  -2,972
  -3,196
  -3,428
  -3,669
  -3,919
  -4,180
  -4,451
  -4,732
  -5,026
  -5,332
  -5,650
  -5,982
  -6,328
Issuance/(repayment) of debt, $m
  150
  73
  82
  91
  100
  109
  117
  125
  134
  141
  149
  157
  164
  172
  179
  187
  195
  202
  210
  219
  227
  236
  245
  255
  265
  276
  288
  300
  312
  325
  339
Issuance/(repurchase) of shares, $m
  28
  479
  571
  672
  781
  899
  1,026
  1,162
  1,305
  1,457
  1,616
  1,783
  1,958
  2,141
  2,331
  2,529
  2,734
  2,948
  3,171
  3,402
  3,642
  3,891
  4,150
  4,420
  4,701
  4,993
  5,297
  5,614
  5,944
  6,289
  6,648
Cash from financing (excl. dividends), $m  
  178
  552
  653
  763
  881
  1,008
  1,143
  1,287
  1,439
  1,598
  1,765
  1,940
  2,122
  2,313
  2,510
  2,716
  2,929
  3,150
  3,381
  3,621
  3,869
  4,127
  4,395
  4,675
  4,966
  5,269
  5,585
  5,914
  6,256
  6,614
  6,987
Total cash flow (excl. dividends), $m
  13
  141
  160
  177
  194
  211
  227
  244
  259
  275
  290
  305
  319
  334
  349
  363
  378
  393
  409
  425
  441
  459
  477
  496
  516
  537
  559
  582
  606
  632
  659
Retained Cash Flow (-), $m
  345
  -479
  -571
  -672
  -781
  -899
  -1,026
  -1,162
  -1,305
  -1,457
  -1,616
  -1,783
  -1,958
  -2,141
  -2,331
  -2,529
  -2,734
  -2,948
  -3,171
  -3,402
  -3,642
  -3,891
  -4,150
  -4,420
  -4,701
  -4,993
  -5,297
  -5,614
  -5,944
  -6,289
  -6,648
Prev. year cash balance distribution, $m
 
  627
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  289
  -411
  -495
  -587
  -689
  -799
  -918
  -1,046
  -1,182
  -1,326
  -1,479
  -1,639
  -1,807
  -1,982
  -2,166
  -2,356
  -2,555
  -2,762
  -2,977
  -3,200
  -3,432
  -3,674
  -3,924
  -4,185
  -4,456
  -4,738
  -5,032
  -5,338
  -5,657
  -5,989
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  277
  -377
  -431
  -483
  -534
  -580
  -620
  -654
  -679
  -695
  -702
  -699
  -687
  -665
  -636
  -599
  -556
  -509
  -458
  -407
  -355
  -305
  -257
  -213
  -173
  -138
  -108
  -83
  -62
  -45
Current shareholders' claim on cash, %
  100
  85.9
  74.0
  64.0
  55.4
  48.0
  41.7
  36.3
  31.7
  27.7
  24.2
  21.2
  18.6
  16.3
  14.3
  12.5
  11.0
  9.7
  8.5
  7.5
  6.6
  5.8
  5.1
  4.5
  4.0
  3.5
  3.1
  2.8
  2.4
  2.1
  1.9

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

FINANCIAL RATIOS  of  Alnylam Pharmaceuticals (ALNY)

Valuation Ratios
P/E Ratio -25.8
Price to Sales 224.7
Price to Book 11.5
Price to Tangible Book
Price to Cash Flow -34.3
Price to Free Cash Flow -28.3
Growth Rates
Sales Growth Rate 14.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 400%
Cap. Spend. - 3 Yr. Gr. Rate 74.7%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 16.3%
Total Debt to Equity 16.3%
Interest Coverage -409
Management Effectiveness
Return On Assets -30.9%
Ret/ On Assets - 3 Yr. Avg. -34.1%
Return On Total Capital -35.1%
Ret/ On T. Cap. - 3 Yr. Avg. -40.4%
Return On Equity -37.5%
Return On Equity - 3 Yr. Avg. -41.2%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -838.3%
EBITDA Margin - 3 Yr. Avg. -754%
Operating Margin -904.3%
Oper. Margin - 3 Yr. Avg. -806.8%
Pre-Tax Margin -872.3%
Pre-Tax Margin - 3 Yr. Avg. -788.6%
Net Profit Margin -872.3%
Net Profit Margin - 3 Yr. Avg. -761.8%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 3.4%
Payout Ratio 0%

ALNY stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ALNY stock intrinsic value calculation we used $47 million for the last fiscal year's total revenue generated by Alnylam Pharmaceuticals. The default revenue input number comes from 2016 income statement of Alnylam Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ALNY stock valuation model: a) initial revenue growth rate of 21.4% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ALNY is calculated based on our internal credit rating of Alnylam Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Alnylam Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ALNY stock the variable cost ratio is equal to 821.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for ALNY stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Alnylam Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Alnylam Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ALNY stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ALNY are equal to 152.1%.

Life of production assets of 4.8 years is the average useful life of capital assets used in Alnylam Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ALNY is equal to -185.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $920 million for Alnylam Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 100.512 million for Alnylam Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Alnylam Pharmaceuticals at the current share price and the inputted number of shares is $12.4 billion.

RELATED COMPANIES Price Int.Val. Rating
SNY Sanofi ADR 39.91 40.06  hold
MRK Merck&Co 56.29 30.23  sell
MDCO Medicines 33.16 1.35  str.sell

COMPANY NEWS

▶ 3 Biotech Stocks Facing Steep Declines   [Feb-13-18 12:20PM  Investopedia]
▶ Alnylam Pharmaceuticals Starts the Wait for Approval   [Feb-12-18 03:37PM  Motley Fool]
▶ Alnylam reports 4Q loss   [Feb-08-18 08:31AM  Associated Press]
▶ 3 Top Cholesterol Drug Stocks to Consider Buying Now   [Feb-06-18 09:04AM  Motley Fool]
▶ Affimed, Alnylam Are End Of The Week Movers In Biotech   [Feb-05-18 10:15AM  Market Exclusive]
▶ 3 Biotech Stocks That Soared This Week: Are They Buys?   [Jan-27-18 10:32AM  Motley Fool]
▶ Why The Medicinces Company Is Having an Outstanding Week   [Jan-24-18 04:41PM  Motley Fool]
▶ Alnylam CEO responds to Trump: Im proud to be a s***holer!   [Jan-12-18 01:00PM  American City Business Journals]
▶ This Is Why Alnylam Pharmaceuticals Soared 249% in 2017   [Jan-10-18 11:28AM  Motley Fool]
▶ Alnylam Announces 2018 Corporate Goals   [Jan-07-18 03:30PM  Business Wire]
▶ Insiders at these 25 Mass. firms netted $771M in stock sales this fall   [Dec-21-17 10:07AM  American City Business Journals]
▶ The 3 Best Biotech Stocks of 2017   [Dec-17-17 09:09AM  Motley Fool]
▶ Alnylam Gets Some Welcome News   [Dec-15-17 03:00PM  Motley Fool]
▶ The FDA Just Blessed A Hemophilia Trial From This Biotech   [11:44AM  Investor's Business Daily]
▶ Sanofi: FDA lifts clinical hold on fitusiran   [07:02AM  GlobeNewswire]
▶ FDA Lifts Clinical Hold on Fitusiran   [07:00AM  Business Wire]
▶ Why Alnylam Pharmaceuticals Rose 12.7% in November   [Dec-06-17 12:47PM  Motley Fool]
▶ A Look at Alnylam Pharmaceuticals" Rolling NDA   [Nov-21-17 12:29PM  GuruFocus.com]
▶ Ionis Pharmaceuticals Inc. Sets Itself Up for Growth   [Nov-14-17 03:44PM  Motley Fool]
▶ Alnylam reports 3Q loss   [Nov-07-17 05:03PM  Associated Press]
Financial statements of ALNY
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.